Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
2seventy bio, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
TSVT
Nasdaq
2834
www.2seventybio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for 2seventy bio, Inc.
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
- Feb 6th, 2025 12:03 pm
US Penny Stocks Spotlight: uCloudlink Group Among 3 Noteworthy Picks
- Jan 21st, 2025 1:05 pm
US Penny Stocks To Watch In December 2024
- Dec 11th, 2024 1:12 pm
US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results
- Nov 15th, 2024 1:58 pm
2seventy bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
- Nov 14th, 2024 1:46 pm
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
- Nov 12th, 2024 12:00 pm
3 Promising US Penny Stocks With At Least $100M Market Cap
- Nov 7th, 2024 1:06 pm
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
- Nov 4th, 2024 9:01 pm
High Growth Tech Stocks To Watch In October 2024
- Oct 24th, 2024 2:04 pm
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
- Sep 25th, 2024 10:00 am
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
- Aug 29th, 2024 11:00 am
2seventy bio, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
- Aug 10th, 2024 12:51 pm
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
- Aug 7th, 2024 11:00 am
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
- Aug 5th, 2024 11:00 am
Broker Revenue Forecasts For 2seventy bio, Inc. (NASDAQ:TSVT) Are Surging Higher
- Jul 4th, 2024 6:24 pm
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
- Jun 26th, 2024 8:11 pm
2seventy bio to Participate in Upcoming Investor Conferences
- May 23rd, 2024 11:00 am
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
- May 8th, 2024 11:00 am
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
- May 3rd, 2024 11:00 am
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
- Apr 5th, 2024 1:05 pm
Scroll